Triazolopyridopyrimidine: A New Scaffold for Dual-Target Small Molecules for Alzheimer's Disease Therapy.

Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry
Lazhar ZribiFakher Chabchoub

Abstract

Alzheimer's disease (AD) is multifactorial disease characterized by the accumulation of abnormal extracellular deposits of amyloid-beta (Aβ) peptide, and intracellular neurofibrillary tangles (NFTs), along with dramatic neuronal death and decreased levels of choline acetyltransferase. Given the limited therapeutic success of available drugs, it is urgent to explore all the opportunities available to combat this illness. Among them, the discovery of new heterocyclic scaffolds binding different receptors involved in AD should offer structural diversity and new therapeutic solutions. In this context, this work describes new triazolopyridopyrimidine easily prepared in good yields showing anticholinesterase inhibition and strong antioxidant power, particularly the most balanced: 6-amino-5-(4-methoxyphenyl)-2-phenyl-[1,2,4]triazolo[1',5':1,6] pyrido[2,3-d]pyrimidine-4-carbonitrile(3c) with IC50 equal to 1.32 μM against AChE and oxygen radical absorbance capacity (ORAC) value equal to 4.01 Trolox equivalents (TE); thus representing a new and very promising hit-triazolopyridopyrimidine for AD therapy.

References

Oct 26, 2002·Journal of Molecular Graphics & Modelling·A MorrealeE Gálvez
Jul 1, 1961·Biochemical Pharmacology·G L ELLMANR M FEATHER-STONE
Jan 8, 2004·Journal of Agricultural and Food Chemistry·Alberto DávalosBegoña Bartolomé
Nov 29, 2007·Expert Opinion on Investigational Drugs·Mercedes VillarroyaManuela G López
Jan 10, 2008·Journal of Medicinal Chemistry·Andrea CavalliCarlo Melchiorre
Oct 28, 2008·Journal of Alzheimer's Disease : JAD·Ashley I Bush
Feb 10, 2009·Current Pharmaceutical Design·Richard Morphy, Zoran Rankovic
Apr 29, 2009·Journal of Computational Chemistry·Garrett M MorrisArthur J Olson
Mar 30, 2010·Current Medicinal Chemistry·V TumiattiC Melchiorre
Jul 28, 2011·Medicinal Research Reviews·Rafael LeónJosé Marco-Contelles
Oct 11, 2013·Dementia and Geriatric Cognitive Disorders·David WilkinsonClaus Goebel
Oct 18, 2013·Journal of Medicinal Chemistry·Michela RosiniCarlo Melchiorre
Jan 15, 2015·Future Medicinal Chemistry·Mohamed BenchekrounJosé Marco-Contelles
Feb 9, 2016·ACS Chemical Neuroscience·Jason D Ulrich, David M Holtzman
May 18, 2016·Current Pharmaceutical Design·Annamaria MartoranaAntonio Palumbo Piccionello
May 16, 2017·Future Medicinal Chemistry·Damijan KnezStanislav Gobec
Jan 16, 2018·Current Topics in Medicinal Chemistry·Lhassane Ismaili, Maria do Carmo Carreiras
Apr 27, 2018·Bioorganic Chemistry·Hanif AhmadManzoor Ahmad

❮ Previous
Next ❯

Methods Mentioned

BETA
pharmacotherapy
X-ray
pharmacotherapies

Software Mentioned

DS
ORAC
FL
AutoDock Vina
AutoDockTools ADT
Discovery Studio
AutoTors

Related Concepts

Related Feeds

Alzheimer's Disease: Amyloid Beta

Alzheimer's disease is a neurodegenerative disease associated with the accumulation of amyloid plaques in the brain; these plaques are comprised of amyloid beta deposits. Here is the latest research in this field.

Related Papers

Journal of Medicinal Food
Deepshikha BhardwajSampath Parthasarathy
Advances in Experimental Medicine and Biology
Leo Tsuda, Young-Mi Lim
Biochimica Et Biophysica Acta. Molecular Cell Research
Benjamin Chun-Kit TongKing-Ho Cheung
© 2021 Meta ULC. All rights reserved